Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Although U.S. stocks closed mostly higher on Monday, there were a few notable insider trades.
Canaccord Genuity analyst Whitney Ijem maintains Sigilon Therapeutics (NASDAQ:SGTX) with a Buy and raises the price target f...
Morgan Stanley analyst Matthew Harrison maintains Sigilon Therapeutics (NASDAQ:SGTX) with a Equal-Weight and raises the pric...
Morgan Stanley analyst Matthew Harrison maintains Sigilon Therapeutics (NASDAQ:SGTX) with a Equal-Weight and raises the pric...
BTIG analyst Thomas Shrader downgrades Sigilon Therapeutics (NASDAQ:SGTX) from Buy to Neutral.
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 200 points on Thursday. The Dow trad...
Gainers Sigilon Therapeutics, Inc. (NASDAQ: SGTX) shares climbed 523.8% to $24.25 after Eli Lilly agreed to acquire the com...
